RERG and colorectal adenocarcinoma: RAS-like estrogen-regulated growth inhibitor (RERG) was first detected in breast cancer using microarray analysis16, after which significantly hypermethylated RERG was observed in colorectal adenocarcinomas but not in adenomas and normal mucosa20.